Skip to main
RNAC

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics Inc. demonstrated a positive outlook stemming from recent clinical advancements, specifically the Phase 2b data showing sustained clinically meaningful improvements with an average MG-ADL reduction of 4.8 at 12-month dosing intervals, outperforming existing FcRn antagonists. The safety profile of Descartes-08 has also been robust, with no observed severe adverse effects, which enhances its potential for broader patient adoption. Additionally, the mechanistic insights provided by correlative biomarkers indicate significant therapeutic benefits, further solidifying the company's innovative stance within the biopharmaceutical sector.

Bears say

Cartesian Therapeutics Inc. experienced a decrease in cash and cash equivalents, falling from $162.1 million in Q2 2025 to $145.1 million in Q3 2025, indicating a significant operating expenditure as the company advances its Phase 3 myasthenia gravis (MG) program. Despite the management's assertion that current cash reserves will fund operations through mid-2027, the market appears to ascribe little value to the company's prospects, as reflected by its low enterprise value of approximately $50 million, given its ongoing clinical programs and regulatory designations. Furthermore, the negative sentiment is exacerbated by a lack of confidence in the therapeutic options currently available for treating autoimmune conditions, as indicated by the underutilization of existing treatments among patients.

RNAC has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Strong Buy based on their latest research and market trends.

According to 4 analysts, RNAC has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.